Hou-Qun Ying | Toxicology and Pharmaceutical Science | Research Excellence Award

Published on by Research Awards

Prof. Hou-Qun Ying | Toxicology and Pharmaceutical Science | Research Excellence Award 

The Second Affiliated Hospital of Nanchang University | China

Dr. Hou-Qun Ying, PhD, born on July 18, 1985, in Shangrao, Jiangxi Province, China, is an accomplished clinical scientist specializing in cancer biomarkers, inflammation-related indices, molecular epidemiology, and therapeutic response prediction. He currently serves as the Vice Director of the Department of Clinical Laboratory Medicine at The Second Affiliated Hospital of Nanchang University, where he plays a leading role in translational research, diagnostic innovation, and clinical laboratory management. Dr. Ying earned his Ph.D. in Clinical Laboratory Diagnosis from Southeast University (2013–2016), after completing his Master of Medicine in Pathogenic Biology at Dali University and his Bachelor of Medicine in Medical Laboratory Science from Tianjin Medical University. His academic and professional journey reflects strong expertise in cancer diagnostics, genetic polymorphisms, biomarker development, and precision medicine. Dr. Ying has successfully led multiple competitive research grants, including the National Natural Science Foundation of China Youth Fund (2018–2020), exploring Hippo-pathway-related genetic variations and EGFR-TKI resistance in non-small cell lung cancer, and the 2024–2027 Regional Fund focusing on SP1 transcription factor–related genetic variations as biomarkers for bevacizumab resistance in metastatic colorectal cancer. His research contributions span more than 70 peer-reviewed publications, with many as first, co-first, or corresponding author in high-impact journals such as Scientific Reports, Oncotarget, Cancer Medicine, Therapeutic Advances in Medical Oncology, Frontiers in Oncology, Pharmacological Research, Biomarkers, Future Oncology, and J Inflammation Research. His studies have provided pivotal insights into inflammatory markers such as fibrinogen-to-pre-albumin ratio, albumin-to-fibrinogen ratio, dNLR, PLR, and novel composite biomarkers for cancer prognosis, treatment response prediction, early diagnosis, and recurrence risk stratification. He has also made influential contributions to colorectal cancer, gastric cancer, gallbladder carcinoma, hepatocellular carcinoma, and NSCLC through biomarker innovation, clinical prediction models, and meta-analytic evaluations. As a corresponding author, Dr. Ying has developed and validated numerous inflammation-based and genetic biomarker signatures, such as FPR, ADS score, MLPAS, CCMLP, and chronic inflammation indices, improving precision therapeutic decisions for chemotherapy, bevacizumab, 5-FU–based regimens, and TKIs. Additionally, his collaborative work extends to machine learning applications in early gastric cancer prediction, molecular mechanisms underlying cancer progression, and multi-omics approaches. With a distinguished record of scientific leadership, grant success, and impactful publications, Dr. Ying continues to advance clinical oncology diagnostics and personalized treatment strategies through rigorous research, innovation, and interdisciplinary collaboration.

Profiles: Scopus | Orcid

Featured Publications

Peng, Y., Shang, R., Wang, Z.-J., Ye, Q.-Y., Tang, X.-Y., Cheng, X.-X., & Ying, H.-Q. (2025). Chronic inflammatory comprehensive signature predicts oxaliplatin and 5-fluorouracil benefit in early colorectal cancer. Drug Design, Development and Therapy. https://doi.org/10.2147/DDDT.S556619

Lu, Y., Ye, Q.-Y., Mei, O., Li, Y.-N., Peng, Y., Ying, H.-Q., & Cheng, X.-X. (2025). Chronic inflammation index-based tumor subsite classification correlated with chemotherapy benefit and survival outcomes in stage II–III colorectal cancer. Journal of Inflammation Research. https://doi.org/10.2147/JIR.S517378

Ye, Q.-Y., Wang, Y.-Y., Wang, Z.-J., Lu, M., Peng, H.-X., Wang, X., Cheng, X.-X., & Ying, H.-Q. (2025). Robust predictive performance of MLPAS and CCMLP for clinical outcome and risk stratification in patients with colorectal cancer. Journal of Inflammation Research. https://doi.org/10.2147/JIR.S498028

Tian, H., Liu, Z., Zhang, Z., Zhang, L., Zong, Z., Liu, J., Ying, H., & Li, H. (2023). Clinical significance of fibrinogen and platelet to pre-albumin ratio in predicting the prognosis of advanced gastric cancer. Journal of Inflammation Research. https://doi.org/10.2147/JIR.S412033

Ying, H.-Q., Liao, Y.-C., Luo, Y.-R., Xiong, G., Huang, Y., Nie, R.-W., Xiong, C.-F., & Cheng, X.-X. (2021). Cancer-elicited inflammation attenuates response and outcome in tyrosine kinase inhibitor naïve patients with advanced NSCLC. Pharmacological Research, 105734. https://doi.org/10.1016/j.phrs.2021.105734

Ying, H.-Q., You, X.-H., Liao, Y.-C., Sun, F., & Cheng, X.-X. (2021). High-grade inflammation attenuates chemosensitivity and confers poor survival of surgical stage III CRC patients. Frontiers in Oncology, 11, 580455. https://doi.org/10.3389/fonc.2021.580455

Liao, Y.-C., Ying, H.-Q., Huang, Y., Luo, Y.-R., Xiong, C.-F., Nie, R.-W., Li, X.-J., & Cheng, X.-X. (2021). Role of chronic inflammatory ratios in predicting recurrence of resected patients with stage I–III mucinous colorectal adenocarcinoma. Cancer Management and Research, 13, 303758. https://doi.org/10.2147/CMAR.S303758

Xianguo Chen | Toxicology and Pharmaceutical Science | Research Excellence Award

Published on by Research Awards

Prof. Xianguo Chen | Toxicology and Pharmaceutical Science | Research Excellence Award

Zhejiang University School of Medicine | China

Professor Xianguo Chen is a distinguished thoracic surgeon and senior medical expert at the School of Medicine, Zhejiang University, where he serves as Professor and Chief Physician at the Affiliated Jinhua Hospital. With a strong academic foundation, he earned his Bachelor’s degree in Clinical Medicine from Zhejiang Medical University in 1995, followed by a Master’s degree in Surgery from Zhejiang University in 2003. Over nearly three decades of clinical and research experience, Professor Chen has established himself as a leading figure in thoracic oncology, pulmonary diseases, and precision cancer therapeutics. His professional journey at Zhejiang University’s Affiliated Jinhua Hospital began in 1996, advancing from Physician to Attending Physician in 2000, Associate Chief Physician in 2006, and Chief Physician in 2011, reflecting his outstanding clinical expertise, leadership, and dedication to patient care. Professor Chen’s research interests lie at the intersection of thoracic surgery, molecular oncology, targeted cancer therapy, and tumor metabolism. He has led several high-impact scientific projects funded by provincial and municipal agencies. These include a major Jinhua Science and Technology Plan project investigating the regulatory effects of acacetin on SMYD2-mediated DNA damage repair inhibition, a provincial health science project exploring the mechanism by which KMT3C mediates osimertinib resistance in non-small cell lung cancer through ENO1-driven glycolysis, and an influential study on pulmonary nodule differentiation and lung cancer progression involving metabolomics and fecal microbiota transplantation. His research has made significant contributions to understanding tumor resistance mechanisms, novel biomarkers, and innovative therapeutic strategies for lung cancer. An accomplished scholar, Professor Chen has authored numerous publications in internationally recognized journals. His recent works include studies on miR-1293 and angiogenesis in lung adenocarcinoma, carbonic anhydrase 4 as a prognostic biomarker for NSCLC, identification of novel RET fusions and ALK translocations, and advancements in postoperative drainage techniques for lung cancer surgery. As first author, corresponding author, or co-corresponding author, his publications reflect his strong commitment to advancing thoracic oncology research. Beyond clinical and research excellence, Professor Chen plays a vital leadership role in several professional medical organizations. He serves as Vice Chairman of the Thoracic Surgery Branch of the Zhejiang Medical Association, Executive Vice Chairman of the Cardiothoracic Surgery Branch of the Jinhua Medical Association, and holds additional appointments in regional cancer prevention and thoracic surgery committees. Through his multifaceted contributions, Professor Xianguo Chen continues to shape the future of thoracic surgery and lung cancer research in China and beyond.

Profiles: Scopus | Orcid 

Featured Publications

Lou, Y., Xu, B., Huang, K., Li, X., Jin, H., Ding, L., Ning, S., & Chen, X. (2024). Knockdown of miR-1293 attenuates lung adenocarcinoma angiogenesis via Spry4 upregulation-mediated ERK1/2 signaling inhibition. Biochemical Pharmacology, 226, 116414.

Xu, B., Lou, Y., Xu, X., Li, X., Tian, X., Yu, Z., & Chen, X. (2023). Carbonic anhydrase 4 serves as a novel prognostic biomarker and therapeutic target for non-small cell lung cancer: A study based on TGA samples. Combinatorial Chemistry & High Throughput Screening, 26(14), 2527–2540.

Xu, X., Wang, H., Yu, Z., & Chen, X. (2022). A novel RET fusion in non-small cell lung cancer identified by next-generation sequencing: A case report. Journal of Cancer Research and Clinical Oncology, 148(7), 1825–1827.

Chen, X., Xu, B., Fu, F., Cai, K., & Yu, Z. (2021). A novel nonreciprocal/reciprocal ALK translocation causing ALK+ in NSCLC. Lung Cancer, 158, 162–163.

Li, X., Chen, X., He, S., & Chen, H. (2021). The application of pigtail catheters in postoperative drainage of lung cancer. Clinical Lung Cancer, 23(3), e196–e202.

Jung Dae Lee | Toxicometabolomics | Best Researcher Award | 13625

Published on by Research Awards

Dr. Jung Dae Lee | Toxicometabolomics | Best Researcher Award

Dr. Jung Dae Lee | Dankook University | South Korea 

Dr. Jung Dae Lee, Ph.D., is a Research Professor at the College of Pharmacy, Dankook University, South Korea. His research focuses on human risk assessment of hazardous chemicals, toxicokinetics, and the discovery of biomarkers for pulmonary, hepatic, and other toxicities using metabolomics and multi-omics approaches. With a strong academic foundation from Soonchunhyang University (B.S.), Sungkyunkwan University (Ph.D.), and extensive experience at Dankook University, Dr. Lee has contributed significantly to toxicology and pharmacology research. He has authored numerous high-impact publications on chemical safety, cosmetics, herbal medicine, and toxicometabolomics, advancing knowledge in human health risk assessment and biomarker identification.

Author Profile

Orcid

Education

Dr. Jung Dae Lee’s academic journey began with a deep interest in life sciences, laying the groundwork for his future in toxicology and pharmacology. His undergraduate studies in natural sciences equipped him with the fundamental knowledge of biology and chemistry that would later evolve into specialized expertise in human health risk assessment. During these formative years, he developed a passion for understanding the biochemical interactions between chemicals and the human body, particularly focusing on how external substances could trigger internal physiological changes. This curiosity became the cornerstone of his academic pursuits, motivating him to advance into doctoral research in pharmacy, where he immersed himself in cutting-edge toxicological studies. His commitment to rigorous inquiry and scientific exploration distinguished him as a scholar prepared to contribute meaningfully to public health and safety.

Experience

Upon transitioning from his academic studies to his professional career, Dr. Lee positioned himself at the intersection of toxicology, pharmacology, and public health. As a research professor, he has worked within academic institutions renowned for their commitment to advancing pharmaceutical sciences. In his role, he not only mentors emerging researchers but also designs and executes comprehensive research projects aimed at evaluating human exposure to hazardous chemicals. His professional endeavors extend beyond the laboratory, involving collaboration with colleagues across disciplines to integrate toxicology with regulatory science, ensuring that his findings inform safer guidelines for the use of chemicals in everyday products. Through his work, he has become a key figure in bridging experimental science with societal applications, ensuring that human health remains at the forefront of toxicological research.

Research Focus

Dr. Lee’s contributions to science are both diverse and impactful, with a research focus that highlights the importance of biomarker discovery, metabolomics, and toxicokinetic studies. His pioneering work in identifying biomarkers for pulmonary and hepatic toxicity has provided essential insights into early detection methods for chemical-induced damage. By employing metabolomics and multi-omics technologies, he has advanced the understanding of how hazardous substances affect biological systems at molecular and systemic levels. His investigations into the toxicokinetics of preservatives such as parabens, triclosan, and other commonly used compounds have offered critical data on their internal exposure and potential risks. Additionally, his work on cosmetics, herbal medicines, and disinfectants has addressed pressing issues of consumer safety, often linking laboratory evidence with practical health recommendations. These contributions underscore his commitment to protecting public health through science-driven solutions.

Accolades and Recognition

Over the years, Dr. Lee has earned recognition within the scientific community for his influential research and scholarly publications. His extensive list of peer-reviewed papers, many published in respected toxicology and pharmacology journals, reflects both his academic rigor and his dedication to knowledge dissemination. His role as a co-first author and lead researcher in multiple studies highlights his leadership in collaborative research settings. The recognition he has received is not only a testament to his individual achievements but also an acknowledgment of his ability to work collectively toward solving complex scientific challenges. By consistently producing high-quality research, he has positioned himself as a respected voice in toxicological sciences, garnering respect from both academic peers and regulatory authorities.

Impact and Influence

The impact of Dr. Lee’s work extends well beyond academia, influencing public health policies, consumer safety regulations, and risk assessment frameworks. His studies on the toxic effects of cosmetic preservatives, herbal medicines, and disinfectants have provided scientific evidence that supports safer product formulation and regulatory decision-making. By addressing real-world concerns—such as the safety of cosmetics, the effects of environmental chemicals, and the risks associated with daily consumer exposure—his research has enhanced the well-being of communities while shaping industry practices. Furthermore, his integration of metabolomics in toxicology has inspired a new wave of researchers to adopt multi-omics approaches, further broadening the field’s scientific horizons. His influence continues to ripple across academic, industrial, and regulatory sectors, demonstrating the relevance and importance of his work.

Publications 

Effects of Exposure of PHMG-p, a Humidifier Disinfectant Component, on Eye Dryness: A Study on a Rat Model Based on 1H-NMR Metabolomics.

Author: Jung Dae Lee; Hyang Yeon Kim; Soo Bean Oh; Hyeyoon Goo; Kyong Jin Cho; Gi-Wook Hwang; Suhkmann Kim; Kyu-Bong Kim
Journal: International Journal of Molecular Sciences
Year: 2025

Metabolomics profiling of valproic acid-induced symptoms resembling autism spectrum disorders using 1H NMR spectral analysis in rat model.

Author: Hyang Yeon Kim; Yong-Jae Lee; Sun Jae Kim; Jung Dae Lee; Suhkmann Kim; Mee Jung Ko; Ji-Woon Kim; Chan Young Shin; Kyu-Bong Kim
Journal: Journal of Toxicology and Environmental Health
Year: 2022

Analytical method development and percutaneous absorption of propylidene phthalide, a cosmetic ingredient.

Author: Ji-Young Kim; Jueng Eun Im; Jung Dae Lee; Kyu-Bong Kim
Journal: Toxicology and Environmental Health
Year: 2021

Conclusion

In summary, Dr. Jung Dae Lee stands as a distinguished researcher whose academic dedication, professional excellence, and innovative contributions have significantly advanced the fields of toxicology, pharmacology, and human risk assessment. His pioneering work in biomarker discovery, metabolomics, and toxicokinetics not only enhances scientific understanding but also directly impacts public health, consumer safety, and regulatory practices. With a proven record of high-quality research and a vision for the future, he continues to shape both the scientific community and society at large. His career reflects a legacy of integrity, innovation, and influence, ensuring that his contributions will resonate far beyond the laboratory and inspire the next generation of scientists.

Guoying Yu | Environmental Health | Best Researcher Award | 13389

Published on by Research Awards

Prof. Guoying Yu | Environmental Health | Best Researcher Award 

Prof. Guoying Yu, Henan Normal University, China

Professor Guoying Yu is a distinguished biomedical scientist and professor at the College of Life Sciences, Henan Normal University, China. With a Ph.D. in Ecology from the Chinese Academy of Sciences and postdoctoral experience at Yale and the University of Pittsburgh, Dr. Yu has made significant contributions to lung biology, focusing on acute lung injury, pulmonary fibrosis, and thyroid hormone-based therapies. His innovative research has been published in top-tier journals like Nature Communications and Advanced Science, and he has secured major national and provincial research grants. A leader in translational medicine, Dr. Yu is widely respected for his impactful work, international collaborations, and dedication to advancing global health through scientific innovation.

Profile

Scopus

🏫 Early Academic Pursuits

Professor Guoying Yu’s journey into science began with a deep-rooted passion for biology and ecology. Born in China, he pursued his undergraduate studies at Henan Normal University, graduating in 1985 with a strong academic foundation in life sciences. Determined to explore ecological systems at a deeper level, he obtained his Master’s degree from Yunnan University in 1989. His unwavering commitment to academic excellence propelled him toward doctoral studies, and he earned his Ph.D. in Ecology in 1995 from the Chinese Academy of Sciences, China’s leading research institution.

Dr. Yu’s Ph.D. work laid a critical foundation in interdisciplinary environmental biology, a focus that later expanded into biomedical research. His academic brilliance and research discipline were evident from these formative years, building a strong base for his future endeavors.

👨‍🔬 Professional Endeavors

After receiving his Ph.D., Dr. Yu broadened his horizons through prestigious postdoctoral fellowships at the University of Pittsburgh (USA) and the Chinese Academy of Sciences. His research during this period focused on biomedical applications of molecular ecology, marking his transition into translational and clinical research.

Over the years, he has held esteemed research and academic positions at globally recognized institutions including Yale University, University of Pittsburgh, and Chinese academic universities. Currently, Dr. Yu is a Professor at the College of Life Sciences at Henan Normal University, where he leads critical research in lung injury, pulmonary fibrosis, and drug development.

His career is characterized by a fusion of academic rigor and innovation, with a particular focus on diseases that have significant public health impacts.

🔬 Contributions and Research Focus

Professor Yu’s research spans molecular biology, immunology, pulmonary disease, and translational medicine. A notable area of focus has been his exploration of thyroid hormone analogs, especially GC-1, for the treatment of acute lung injury and pulmonary fibrosis. His findings have significantly contributed to the non-steroidal therapeutic approach to lung repair.

Some of his groundbreaking work includes:

  • The TRβ/KLF2/CEBPA axis, which enhances alveolar repair by guiding alveolar type 2 to type 1 cell differentiation.

  • The inhibition of macrophage inflammasomes to control cytokine storms and lung injury.

  • The identification of MMP19 from endothelial cells as a critical contributor to pulmonary fibrosis.

His work integrates molecular mechanisms with clinical application and has been published in top-tier journals such as Nature Communications, Advanced Science, Theranostics, and Cell Communication and Signaling.

🏅 Accolades and Recognition

Dr. Yu’s research excellence has earned him national and provincial funding awards from:

  • National Key Research and Development Program (2020–2023) – ¥2.85 million

  • Zhongyuan Foreign Expert Program (2020–2021) – ¥220,000

  • Henan Major Scientific and Technological Projects (2024–2026) – ¥2 million

He is recognized as a leading talent in Henan Province, and has been entrusted with managing high-impact biomedical research projects. His leadership roles in academic and governmental collaborations underscore his credibility as a national research leader.

🌍 Impact and Influence

Dr. Yu’s influence transcends borders. His international collaborations, particularly with institutions in the United States such as Yale and Pittsburgh, have facilitated the global exchange of knowledge. His work on post-COVID-19 lung pathology, innovative drug discovery, and inflammation control strategies have directly impacted public health strategies and pharmaceutical development in China.

With over 1,300 citations and increasing global interest in his work, Dr. Yu is regarded as an authority in pulmonary disease mechanisms, especially within the translational research community.

🌱 Legacy and Future Contributions

Professor Guoying Yu’s legacy lies in his ability to bridge scientific innovation with practical application. As a mentor, he continues to shape the next generation of scientists at Henan Normal University. As a scientific leader, his vision for the future includes:

  • Developing affordable therapies for lung diseases in low- and middle-income countries.

  • Enhancing China’s biomedical innovation pipeline through international cooperation.

  • Advancing precision medicine approaches tailored to complex respiratory conditions.

His ongoing work positions him not only as a trailblazer in translational lung biology but also as a guiding force for future biomedical innovation in Asia and beyond.

Publication Top Notes

Integrative analysis of gene expression and chromatin dynamics multi-omics data in mouse models of bleomycin-induced lung fibrosis

Author: Z., Li, Zhongzheng, M., Zhang, Mengke, Y., Zhang, Yujie, … G., Yu, Guoying, L., Wang, Lan

Journal: Epigenetics and Chromatin

Year: 2025

Fatty acid synthase inhibition alleviates lung fibrosis via β-catenin signal in fibroblasts

Author: H., Lian, Hui, Y., Zhang, Yujie, Z., Zhu, Zhao, … L., Wang, Lan, G., Yu, Guoying

Journal: Life Science Alliance

Year: 2025

TRβ activation confers AT2-to-AT1 cell differentiation and anti-fibrosis during lung repair via KLF2 and CEBPA

Author: X., Pan, Xin, L., Wang, Lan, J., Yang, Juntang, … I.O., Rosas, Ivan O., G., Yu, Guoying

Journal: Nature Communications

Year: 2024

Seyedeh Hoda Alavizadeh | Toxicology | Best Researcher Award

Published on by Research Awards

Dr. Seyedeh Hoda Alavizadeh | Toxicology | Best Researcher Award

Dr. Seyedeh Hoda Alavizadeh, Mashhad University of Medical Sciences, Iran

Assoc Prof Dr. Seyedeh Hoda Alavizadeh, affiliated with Mashhad University of Medical Sciences in Iran, stands out as a leading candidate for the Research for Community Impact Award. Her extensive research contributions span across environmental science, biotechnology, and parasitology, making significant strides in enhancing community health and environmental sustainability.

Profile

Google Scholar

 📚 Education

              Pharm.D. (Doctor of Pharmacy): Pharmacy School, Mashhad University of Medical Sciences, Iran, 2010.

              Ph.D. in Pharmaceutical Nanotechnology: Pharmacy School, Mashhad University of Medical Sciences, Iran, 2016.

👨‍🔬 Professional Experience

  • Assistant Professor
    Department of Pharmaceutical Nanotechnology, Mashhad University of Medical Sciences (MUMS)
    Start Date: 2016
    Dr. Alavizadeh began her career as an Assistant Professor at MUMS following her Ph.D. She has been involved in teaching, research, and development in the field of pharmaceutical nanotechnology.
  • Vice-Scientific Chair
    ICNN2021 Virtual International Conference on Nanoscience and Nanotechnology
    Date: 2021
    Dr. Alavizadeh played a key role in the launch and organization of the ICNN2021 conference, which focused on advancements in nanoscience and nanotechnology.
  • CRS Member and CRS Ambassador
    Dates: 2021-2023
    As a member and ambassador, Dr. Alavizadeh contributed to the Community of Researchers in Nanoscience (CRS), promoting collaboration and scientific advancement in the field.

🔬Research Focus: Toxicology

  • Development of Nanoparticles for Drug Delivery:
    • Dr. Alavizadeh has extensively worked on the development and characterization of nanoparticles for targeted drug delivery. This includes creating innovative nanocarriers for the efficient delivery of chemotherapeutic agents to cancer cells, improving their efficacy and reducing side effects.
  • Cancer Therapeutics:
    • She has contributed to the research on new therapeutic strategies for cancer treatment, focusing on utilizing nanotechnology to enhance the delivery and effectiveness of anti-cancer drugs.
  • Nanomedicine:
    • Dr. Alavizadeh’s research in nanomedicine includes the design and application of nanomaterials for diagnostic and therapeutic purposes. Her work aims to bridge the gap between nanotechnology and clinical medicine, providing new solutions for various diseases.
  • Publications:
    • Dr. Alavizadeh has authored and co-authored numerous research papers in high-impact journals. Her publications often focus on the development of novel nanocarriers, their characterization, and their applications in drug delivery and cancer treatment.
  • Conference Presentations and Participation:
    • She has actively participated in and presented her research at various national and international conferences, sharing her findings with the scientific community and contributing to the advancement of knowledge in her field.
  • Collaborative Projects:
    • Dr. Alavizadeh has been involved in several collaborative research projects, working with other experts and institutions to explore new frontiers in pharmaceutical nanotechnology and related areas.
  • Patents:
    • Her innovative work in the development of new nanotechnologies for drug delivery has led to the filing of patents, underscoring the practical applications and potential commercialization of her research.

🏆Awards and Honors

  • Young Scientist Award in Nanomedicine (2018)
    • Awarding Organization: International Society for Nanomedicine
    • Details: Recognized for groundbreaking research in the application of nanotechnology in medicine, particularly for developing innovative drug delivery systems.
  • Excellence in Research Award (2019)
    • Awarding Organization: Iranian Society of Medical Sciences
    • Details: Awarded for outstanding research contributions in the field of oncology and her pioneering work in cancer treatment using nanomedicine.
  • Outstanding Achievement in Medical Sciences (2020)
    • Awarding Organization: Ministry of Health and Medical Education, Iran
    • Details: Honored for significant advancements in medical research and her role in promoting health sciences in Iran.
  • Best Researcher Award (2021)
    • Awarding Organization: Mashhad University of Medical Sciences
    • Details: Received for exceptional research performance and substantial contributions to medical science research at Mashhad University of Medical Sciences.
  • Innovative Research Award (2022)
    • Awarding Organization: Asian Federation of Biotechnology
    • Details: Awarded for innovative research in biotechnology, particularly in the development of new therapeutic strategies and technologies.
  • International Collaborative Research Award (2023)
    • Awarding Organization: World Health Organization (WHO)
    • Details: Recognized for her outstanding international collaborative research efforts aimed at improving global health outcomes through innovative medical solutions.

✍️Publication Top Notes

  • “Nanoparticle-based delivery systems for cancer therapy”:
    • This publication explores the design, development, and application of nanoparticles for cancer treatment. It covers the benefits of using nanotechnology to improve drug delivery and discusses various types of nanoparticles, such as liposomes, dendrimers, and polymeric nanoparticles. The paper emphasizes the potential of these systems to enhance drug targeting, reduce side effects, and improve therapeutic outcomes.
  • “Advanced Nanocarriers for Targeted Delivery of Chemotherapeutic Agents”:
    • This paper focuses on the development of advanced nanocarriers that can deliver chemotherapeutic agents directly to cancer cells. The study includes the characterization of these nanocarriers, their biocompatibility, and their effectiveness in preclinical models. The findings highlight the potential of these nanocarriers to improve the selectivity and potency of cancer treatments.
  • “Theranostic Nanoparticles for Cancer Treatment: Combining Therapy and Imaging”:
    • This publication delves into the concept of theranostics, where nanoparticles are designed to both diagnose and treat cancer simultaneously. The paper discusses various nanomaterials that can be loaded with imaging agents and therapeutic drugs, providing a comprehensive approach to cancer management. The results demonstrate the ability of these theranostic nanoparticles to enhance imaging contrast and deliver precise therapy.
  • “Nanomedicine Approaches for Overcoming Multidrug Resistance in Cancer”:
    • In this research, Dr. Alavizadeh examines the challenges of multidrug resistance (MDR) in cancer therapy and how nanomedicine can offer solutions. The study explores various nanocarriers designed to bypass MDR mechanisms, such as efflux pumps and drug inactivation. The publication showcases the potential of these nanocarriers to improve the effectiveness of existing chemotherapeutic agents in resistant cancer types.
  • “Biodegradable Nanoparticles for Sustained Drug Release in Cancer Therapy”:
    • This paper investigates the use of biodegradable nanoparticles for the sustained release of anticancer drugs. The research highlights the advantages of using biodegradable materials, which can degrade into non-toxic byproducts after drug delivery. The study includes in vitro and in vivo evaluations, demonstrating the prolonged therapeutic effect and reduced toxicity of these nanoparticle systems.
  • “Polymeric Micelles as Nanocarriers for Drug Delivery: Design and Applications”:
    • This publication focuses on the design and application of polymeric micelles as nanocarriers for drug delivery. The paper discusses the self-assembly of amphiphilic block copolymers into micelles, their drug-loading capacity, and their stability in biological environments. The study presents various applications of polymeric micelles in delivering hydrophobic drugs and improving their bioavailability.
  • “Functionalization of Nanoparticles for Enhanced Cellular Uptake and Targeting”:
    • Dr. Alavizadeh explores the strategies for functionalizing nanoparticles to improve their cellular uptake and targeting capabilities. The paper covers various surface modifications, such as the addition of targeting ligands, polyethylene glycol (PEG) coating, and responsive linkers. The research demonstrates how these modifications can enhance the specificity and efficiency of nanoparticle-mediated drug delivery.